New therapeutic principles for adverse effects on upper and lower gastrointestinal tract in patients treated with opioid analgesics

Allan, 2001, Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain, Br Med J, 322, 1154, 10.1136/bmj.322.7295.1154 Allan, 2005, Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain, Spine, 30, 2484, 10.1097/01.brs.0000186860.23078.a8 Ballantyne, 2007, Opioid dependence and addiction during opioid treatment of chronic pain, Pain, 129, 235, 10.1016/j.pain.2007.03.028 Bell, 2009, The prevalence, severity, and impact of opioid-induced bowelk dysfunction: Results of a US and European patient survey (PROBE 1), Pain Med, 10, 35, 10.1111/j.1526-4637.2008.00495.x Breivik, 2009, Cancer-related pain: a pan-European survey of prevalence, treatment and patient attitudes, Ann Oncol, 10.1093/annonc/mdp001 Brennscheidt, 2000, Pharmacokinetics of nortilidine and naloxone after administration of tilidine/naloxone solution or tilitine/naloxone sustained release tablets, Arzneimittelforschung, 50, 1015 Brennscheidt, 2007, Pharmacokinetics of tilidine and naloxone in patients with severe hepatic impairment, Arzneimittelforschung, 57, 106 Chou, 2009, Opioid Treatment Guidelines: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain, J Pain, 10, 113, 10.1016/j.jpain.2008.10.008 Colvin, 2006, The difficult pain, Br Med J, 332, 1081, 10.1136/bmj.332.7549.1081 Cook, 2008, Gastrointestinal side effects in chronic opioid users: results from a population-based survey, Aliment Pharmacol Ther, 27, 1224, 10.1111/j.1365-2036.2008.03689.x Culpepper-Morgan, 1992, Treatment of opioid-induced constipation with oral naloxone: a pilot study, Clin Pharmacol Ther, 52, 90, 10.1038/clpt.1992.106 De Schepper, 2004, Opioids and the gut: pharmacology and current clinical experience, Neurogastroenterol Motil, 16, 383, 10.1111/j.1365-2982.2004.00513.x DeLuca, 1996, Insights into opioid action in the intestinal tract, Pharmacol Ther, 69, 103, 10.1016/0163-7258(95)02053-5 Delaney, 2004, Clinical perspective on postoperative ileus and the effect of opiates, Neurogastroenterol Motil (Suppl 2), 16, 61, 10.1111/j.1743-3150.2004.00559.x Fahy, 2005, Postoperative bowel dysfunction, 121 Holzer, 2008, New approaches to the treatment of opioid-induced constipation, Eur Rev Med Pharmacol Sci, 12, 119 Kalso, 2004, Opioids in chronic non-cancer pain: systematic reviewof efficacy and safety, Pain, 112, 372, 10.1016/j.pain.2004.09.019 Kurz, 2003, Opioid-induced bowel dysfunction: pathophysiology and potential new therapies, Drugs, 63, 649, 10.2165/00003495-200363070-00003 Ling, 1989, Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model, Life Sci, 45, 1627, 10.1016/0024-3205(89)90272-5 Ludwig, 2008, Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway, Arch Surg, 143, 1098, 10.1001/archsurg.143.11.1098 McNicol, 2003, Management of opioid side-effects in cancer-related and chronic noncancer pain: a systematic review, J Pain, 4, 231, 10.1016/S1526-5900(03)00556-X McNicol, 2008, Efficacy and safety of mu-opioid anatagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials, Pain Med, 9, 634, 10.1111/j.1526-4637.2007.00335.x Meissner, 2009, A randomized controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation, Eur J Pain, 13, 56, 10.1016/j.ejpain.2008.06.012 Mythen, 2005, Postoperative gastrointestinal tract dysfunction, Anesth Analg, 100, 196, 10.1213/01.ANE.0000139376.45591.17 Paulson, 2005, Alvimopan: an oral, peripherally acting, muopioid receptor antagonist for the treatment of opioid-induced bowel dysfunction a 21-day treatment randomized clinical trial, J Pain, 6, 184, 10.1016/j.jpain.2004.12.001 Portenoy, 2008, Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: A double-blind, randomized, parallel group, dose-ranging study, J Pain Symptom Manage, 35, 458, 10.1016/j.jpainsymman.2007.12.005 Quigley, 2005, The role of opioids in cancer pain, Br Med J, 331, 825, 10.1136/bmj.331.7520.825 Reimer, 2009, Meeting the challenges of opioid-induced constipation in chronic pain management a novel approach, Pharmacology, 83, 10, 10.1159/000165778 Russell, 1982, Antagonism of gut, but not central effects of morphine with quarternary narcotic antagonists, Eur J Pharmacol, 78, 255, 10.1016/0014-2999(82)90026-7 Schook, 1987, Peptide opioid anatagonist separates peripheral and central opioid antitransit effects, J Pharmacol Exp Ther, 243, 492 Swegle, 2006, Management of common opioid-induced adverse effects, Am Fam Physician, 74, 1347 Taguchi, 2001, Selective postoperative inhibition of gastrointestinal opioid receptors, N Engl J Med, 345, 935, 10.1056/NEJMoa010564 Thomas, 2008, Methylnaltrexone for opioid-induced constipation in advanced illness, N Engl J Med, 358, 23321, 10.1056/NEJMoa0707377 Thorpe, 2001, Management of opioid-induced constipation, Curr Pain Headache Rep, 5, 237, 10.1007/s11916-001-0037-7 Vodracova, 2008, Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain, J Pain, 9, 1144, 10.1016/j.jpain.2008.06.014 Webster, 2008, Pain, 137, 428, 10.1016/j.pain.2007.11.008 Weinstein, 1971, Metabolites of naloxone in human urine, J Pharm Sci, 60, 1567, 10.1002/jps.2600601030